期刊文献+

多发性硬化干扰素β治疗效果初步观察

Preliminary Report on the Efficacy of Interferon β in 6 Chinese Patients with Multiple Sclerosis
下载PDF
导出
摘要 目的初步探讨干扰素(IFN-β)用于中国早期多发性硬化(MS)的疗效。方法对6例MS患者采用IFN-β治疗,并随访4~27个月。根据扩展的功能缺损状况量表评分(EDSS)、磁共振(MRI)T2加权病灶演变及持续缓解的时间,综合评价IFN-β的治疗疗效。结果6例患者随访期EDSS评分明显改善,T2W病灶负荷明显缩小。无复发者。结论IFN-β用于中国MS患者能改善其神经功能障碍.并减少复发。 Objective To evaluate the efficacy of interferon β (IFN-β) in Chinese patients with muhiple sclerosis(MS) at early stage. Methods Six patients with MS were treated with IFN-β,and be followed up for 4- 27 months. The data of expanded disability status(EDSS), T2-weighted lesion load on MRI and the remitting duration after treatment were analyzed together to evaluate the therapeutic efficacy of IFN-β. Results After treatment, EDSS scores of all 6 MS patients were decreased by one or more points. T2-weighted lesion burdens were also decreased. During follow-up, no one relapsed. Conclusions IFN-β could improve the neurological disability and reduce the relapse of MS.
出处 《中国神经免疫学和神经病学杂志》 CAS 2006年第6期331-334,共4页 Chinese Journal of Neuroimmunology and Neurology
关键词 多发性硬化 干扰素Β 治疗 multiple sclerosist interferon beta therapy
  • 相关文献

参考文献13

  • 1The IFNβ Multiple Sclerosis Study Group.Interferon beta-1b is effective in relapsing-remitting multiple sclerosis.Ⅰ.Clinical results of a multicenter,randomized,double-blind,placebo-controlled trial[J].Neurology,1993,43:655-661.
  • 2The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.Interferon beta-1b in the treatment of multiple sclerosis:final outcome of the randomized controlled trial[J].Neurology,1995,45 (7):1277-1285.
  • 3Poser CM,Paty DW,Scheinberg L,et al.New diagnostic criteria for multiple sclerosis:guidelines for research protocols[J].Ann Neurol,1983,13:227-231.
  • 4Kurtzke JF.Rating neurological impairment in multiple sclerosis:an expanded disability status scale (EDSS)[J].Neurology,1983,33:1444-1452.
  • 5Rovaris M,Gambini A,Gallo A,et al.Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution[J].Neurology,2005,65:1626-1630.
  • 6Lin X,Tench CR,Turner B,et al.Spinal cord atrophy and disability in multiple sclerosis over four years:application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon[J][beta[J]]-1a (Rebif) treatment trial[J].Neurol Neurosurg Psychiatry,2003,74:1090-1094.
  • 7Robert A,Srinivas R,Richard A,et al.Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity[J].Arch Neurol,2005,62:1371-1376.
  • 8Kinkel RP,Kollman C,Glassman A,et al.Interferon beta-1a (Avonex)delays the onset of clinically definite MS over 5 years of treatment:results from CHAMPIONS study[J].Neurology,2004,62(suppl 5):A261-262
  • 9Comi G,Fillippi M,Barkhof F,et al.Effect of early interferon treatment on conversion to definite multiple sclerosis:a randomized study[J].Lancet,2001,357(9268):1576-1582.
  • 10Suhayl Dhib-Jalbut.Mechanisms of action of interferons and glatiramer acetate in multiple scleosis[J].Neurology,2002,58(8 suppl 4):S3-S9.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部